Successful total hip replacement with sequential administration of bypassing agents in an adolescent boy with hemophilia A and high inhibitor titers

KAYA Z., Orhan O., Turanli S., Yenicesu I., KOÇAK Ü., Gursel T.

BLOOD COAGULATION & FIBRINOLYSIS, cilt.28, sa.5, ss.419-422, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1097/mbc.0000000000000617
  • Dergi Adı: BLOOD COAGULATION & FIBRINOLYSIS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.419-422
  • Gazi Üniversitesi Adresli: Evet

Özet

There are only a few reports of total hip replacement in patients with hemophilia A and inhibitors. We performed total hip replacement in an 18-year-old adolescent boy who had high inhibitor titers since infancy. Recombinant factor VIIa (NovoSeven) was used as a bypass agent during the surgery. There was no excessive introperative bleeding; however, postsurgical bleeding occurred and was controlled by sequential administration of recombinant factor VIIa and activated prothrombin complex concentrate (FEIBA). This is the first report of this treatment modality in such a major surgery. Sequential bypassing agent therapy can be effective for treating refractory bleeding in hemophilia patients who have high inhibitor titers but require major surgery. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.